FDA Looks Likely To Split Decision On Mepolizumab Approval
This article was originally published in The Pink Sheet Daily
Executive Summary
An advisory committee was nearly unanimous that GSK’s clinical program demonstrated efficacy and safety for the IL-5 inhibitor in adult patients with severe asthma, but voted no on approval in patients ages 12-17.
You may also be interested in...
Breo Ellipta Stumbles On Pediatric Asthma Claim, But Advair Helps Break The Fall
FDA approves GlaxoSmithKline’s LABA/inhaled corticosteroid combo for asthma in adults but says more data needed in adolescents. GSK plans to throw additional promotional support behind the existing pediatric asthma claim for Advair, which is expected to face generic competition in the coming years.
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.